The line-up consists of supplements to meet the health needs to patients taking GLP-1 medications for weight loss.
Stock.adobe.com
With more people taking GLP-1s for weight-loss, it’s becoming clear that these people must take certain steps to maintain their health alongside the medication use. GLP-1’s are effective at weight management due to their appetite reducing effects. For people taking these medications, this means they must be careful to ensure that they’re still consuming a healthy spread of micro and macro nutrients on a daily basis.
The Vitamin Shoppe announced a new line of supplements designed specifically for people on GLP-1s for weight-loss.1 The line-up of products contains a meal-replacement powder which is high in protein and vitamins, along with a fiber supplement, and a general multivitamin supplement. The line-up also contains a heavy protein powder that also contains collagen, as skin health is a recurring issue for people taking GLP-1s.
In a press release, The Vitamin Shoppe president Muriel Gonzalez said, “With the surge in GLP-1 medication use for weight loss, we recognized a critical gap in the market for tailored nutritional support. GLP-1 medications can significantly impact appetite, digestion, and nutrient absorption, making supplementation essential. Building on the expertise of The Vitamin Shoppe's Whole Health Rx telehealth platform, we developed these new GLP-1 Support products as an easy-to-understand, one-stop solution for consumers seeking a balanced and holistic approach to weight loss and nutrient supplementation."
Tabitha Daley is a registered dietitian nutritionist who works with The Vitamin Shoppe. She helped formulate these supplements. In the same press release, she added, “GLP-1 users face specific nutritional challenges and finding products tailored to these needs can be challenging. Our goal was to create an accessible, science-backed system that fills essential nutrient gaps, while also helping individuals feel their best throughout their weight-loss journey by addressing nutrition-related issues that are associated with GLP-1 drugs."
One of the most well-known GLP-1s is Wegovy. The drug’s maker, Novo Nordisk, recently took steps to reduce the cost of the drug for cash-paying patients.2 A monthly supply of the drug will cost $499 when patients purchase it through the Wegovy savings offer, which will be available at pharmacies across the country.
At the time of the announcement, Novo Nordisk’s executive vice president of US operations and global business development and president of Novo Nordisk Inc. Dave Moore said in a press release, “At Novo Nordisk, we are committed to developing innovative medicines and will continue to prioritize making them accessible to and affordable for the communities we serve. With the evolution of our Wegovy® savings program, we continue to deliver options that empower people living with obesity to more easily pursue their weight management and health goals."
The pricing offer was originally announced as part of Novo Nordisk’s direct-to-patient pharmacy NovoCare.3 The service was launched in early March.
At the time, Moore said, “Novo Nordisk continues to advance solutions for patients that improve affordability and access to our medicines, whether they have insurance or not. Today, over 55 million people in the U.S. have coverage specifically for weight management medicines, and 90% of Wegovy® patients with coverage pay $0 to $25 a month for Wegovy®. With NovoCare® Pharmacy, patients and prescribers alike have another option that provides convenient access to all doses of real, FDA-approved Wegovy® at a reduced cost in our high-quality pen."
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Social Media's Influence on Young Women's Reproductive Decisions
February 20th 2025In this Q&A, Organon's Chief Communications Officer, Becky Edwards discusses how much social media and influencers sway decisions about birth control methods, potential consequences of these misinformed choices, and more.